Kinetics and mechanism of L-[3H]nicotine binding to putative high affinity receptor sites in rat brain

PM Lippiello, SB Sears and KG Fernandes

The properties of high affinity nicotine-binding sites in rat brain were studied by monitoring the kinetics of L-[3H]nicotine binding to whole brain membrane preparations, including both total membranes and membrane subfractions. Although nicotine appeared to bind to a single class of sites, with an apparent equilibrium dissociation constant of 2- 3 nM, the binding kinetics were biphasic at all temperatures and at all nicotine concentrations tested. An initial rapid binding process, with an association rate constant of around 0.02 min-1 nM-1 at 0 degree, was followed by a slower binding process. Both the rate and the proportion of binding that occurred by the slower process were dependent on the nicotine concentration. By comparison, the kinetics of dissociation were first order at all concentrations, with a rate constant of 0.04 min-1 at 0 degree. The rates of both association and dissociation increased significantly with temperature, but there was no changed in the apparent affinity of the sites. The same results were obtained with several different membrane preparations, including whole brain membrane preparations, detergent-permeabilized membranes, P-2 fractions, and synaptosomes. The results were found to be consistent with a two-state model. Analyses based on this model indicate that the binding sites can assume two different conformations, one having a high affinity (KD = 1 nM) and the other a low affinity (KD = 150 nM) for nicotine. It was estimated that approximately 60% of the sites are in the low affinity conformation in the absence of ligand. However, the evidence suggests that nicotine binding can facilitate a shift in the conformational equilibrium, favoring the high affinity state.

Volume 31, Issue 4, pp. 392-400, 04/01/1987
Copyright © 1987 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				V. I. Pidoplichko, J. Noguchi, O. O. Areola, Y. Liang, J. Peterson, T. Zhang, and J. A. Dani Nicotinic Cholinergic Synaptic Mechanisms in the Ventral Tegmental Area Contribute to Nicotine Addiction Learn. Mem., January 1, 2004; 11(1): 60 - 69. [Abstract] [Full Text] [PDF]

				J. R. A. Wooltorton, V. I. Pidoplichko, R. S. Broide, and J. A. Dani Differential Desensitization and Distribution of Nicotinic Acetylcholine Receptor Subtypes in Midbrain Dopamine Areas J. Neurosci., April 15, 2003; 23(8): 3176 - 3185. [Abstract] [Full Text] [PDF]

				L. H. Wilkins Jr., V. P. Grinevich, J. T. Ayers, P. A. Crooks, and L. P. Dwoskin N-n-Alkylnicotinium Analogs, a Novel Class of Nicotinic Receptor Antagonists: Interaction with alpha 4beta 2* and alpha 7* Neuronal Nicotinic Receptors J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 400 - 410. [Abstract] [Full Text] [PDF]

				C. P. Fenster, T. L. Whitworth, E. B. Sheffield, M. W. Quick, and R. A. J. Lester Upregulation of Surface alpha 4beta 2 Nicotinic Receptors Is Initiated by Receptor Desensitization after Chronic Exposure to Nicotine J. Neurosci., June 15, 1999; 19(12): 4804 - 4814. [Abstract] [Full Text] [PDF]

				L. Ke, C. M. Eisenhour, M. Bencherif, and R. J. Lukas Effects of Chronic Nicotine Treatment on Expression of Diverse Nicotinic Acetylcholine Receptor Subtypes. I. Dose- and Time-Dependent Effects of Nicotine Treatment J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 825 - 840. [Abstract] [Full Text]

				P. Whiteaker, C. G. V. Sharples, and S. Wonnacott Agonist-Induced Up-Regulation of alpha 4beta 2 Nicotinic Acetylcholine Receptors in M10 Cells: Pharmacological and Spatial Definition Mol. Pharmacol., May 1, 1998; 53(5): 950 - 962. [Abstract] [Full Text]

				M. Bencherif, J. D. Schmitt, B. S. Bhatti, P. Crooks, W. S. Caldwell, M. E. Lovette, K. Fowler, L. Reeves, and P. M. Lippiello The Heterocyclic Substituted Pyridine Derivative (±)-2-(-3-pyridinyl)-1-Azabicyclo[2.2.2]octane (RJR-2429): A Selective Ligand at Nicotinic Acetylcholine Receptors J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 886 - 894. [Abstract] [Full Text]

				J. P. Sullivan, D. Donnelly-Roberts, C. A. Briggs, D. J. Anderson, M. Gopalakrishnan, I. C. Xue, M. Piattoni-Kaplan, E. Molinari, J. E. Campbell, D. G. Mckenna, et al. ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A Potent and Selective Cholinergic Channel Modulator with Neuroprotective Properties J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 235 - 246. [Abstract] [Full Text]

				S. R. Grady, E. U. Grun, M. J. Marks, and A. C. Collins Pharmacological Comparison of Transient and Persistent [3H]Dopamine Release from Mouse Striatal Synaptosomes and Response to Chronic L-Nicotine Treatment J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 32 - 43. [Abstract] [Full Text]